Amgen

Amgen, a US-based Pharmaceutical Preparation Manufacturing company, reported its 2024 Scope 1 emissions as approximately 147.35 million kg CO2e, with Scope 2 emissions (market-based) at about 13.89 million kg CO2e, and Scope 3 emissions totalling approximately 1.705 billion kg CO2e. This includes about 945.76 million kg CO2e from purchased goods and services, and approximately 220.98 million kg CO2e from capital goods.

The company has set several climate commitments. Amgen aims for carbon neutrality for its owned and operated facilities (Scope 1 and Scope 2 emissions) by 2027. It is also striving for 100% renewable electricity use at all feasible operations by 2027, which is expected to result in an approximate 50% reduction in operational carbon emissions (Scope 2).

Amgen has Science Based Targets initiative (SBTi) approved targets, committing to reduce absolute Scope 1 and Scope 2 greenhouse gas emissions by 55% by 2027 from a 2019 base year. Additionally, Amgen plans to increase its annual sourcing of renewable electricity from 29% in 2019 to 100% by 2027, and maintain this through 2030. The company further commits that 73% of its suppliers by spend, covering upstream purchased goods and services and capital goods, will have science-based targets by 2027.

As of 2023, Amgen had achieved 54% of its targeted reductions for Scope 1 and Scope 2 carbon emissions against its 2019 baseline.